Curis, Inc. (NASDAQ:CRIS) Short Interest Update

Curis, Inc. (NASDAQ:CRIS) saw a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 137,000 shares, an increase of 26.6% from the October 15th total of 108,200 shares. Based on an average daily volume of 55,800 shares, the days-to-cover ratio is presently 2.5 days. Currently, 1.8% of the shares of the company are short sold.

Curis Stock Performance

Shares of CRIS opened at $3.95 on Friday. The company’s 50 day simple moving average is $5.01 and its 200-day simple moving average is $7.12. Curis has a 12-month low of $3.51 and a 12-month high of $17.49.

Institutional Trading of Curis

A number of large investors have recently bought and sold shares of CRIS. Vanguard Group Inc. increased its stake in Curis by 4.8% in the first quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock valued at $2,376,000 after purchasing an additional 10,097 shares during the period. Point72 Asset Management L.P. grew its holdings in shares of Curis by 795.5% during the second quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock worth $748,000 after buying an additional 96,256 shares during the last quarter. Focused Wealth Management Inc grew its holdings in shares of Curis by 63.1% during the third quarter. Focused Wealth Management Inc now owns 54,066 shares of the biotechnology company’s stock worth $291,000 after buying an additional 20,908 shares during the last quarter. Finally, CM Management LLC increased its position in Curis by 380.0% in the 1st quarter. CM Management LLC now owns 120,000 shares of the biotechnology company’s stock valued at $1,304,000 after acquiring an additional 95,000 shares during the period. Institutional investors and hedge funds own 29.97% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Curis in a report on Friday.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.